Ontology highlight
ABSTRACT: Background
Anderson-Fabry disease (AFD) is an inborn lysosomal enzymopathy resulting from the deficient or absent activity of the lysosomal exogalactohydrolase, α-galactosidase A. This deficiency, results in the altered metabolism of glycosphingolipids which leads to their accumulation in lysosomes, thus to cellular and vascular dysfunction. To date, numerous mutations (according to recent data more than 1000 mutations) have been reported in the GLA intronic and exonic mutations. Traditionally, clinical manifestations are more severe in affected hemizygous males than in females. Nevertheless, recent studies have described severe organ dysfunction in women.The aim of the study
This study reports clinical, biochemical, and molecular findings of the members of three Sicilian families. The clinical history of these patients highlights a remarkable interfamilial and intrafamilial phenotypic variability which characterizes Fabry disease relative to target organs and severity of clinical manifestations.Discussion
Our findings, in agreement with previous data, report a little genotype-phenotype correlation for the disease, suggesting that the wide phenotypic variability of Anderson-Fabry disease is not completely ascribable to different gene mutations but other factors and mechanisms seem to be involved in the pathogenesis and clinical expression of the disease. Moreover, this study emphasies the importance of pedigree analysis in the family of each proband for identifying other possibly affected relatives.
SUBMITTER: Tuttolomondo A
PROVIDER: S-EPMC5617434 | biostudies-literature | 2017 Sep
REPOSITORIES: biostudies-literature

Tuttolomondo Antonino A Simonetta Irene I Duro Giovanni G Pecoraro Rosaria R Miceli Salvatore S Colomba Paolo P Zizzo Carmela C Nucera Antonia A Daidone Mario M Di Chiara Tiziana T Scaglione Rosario R Della Corte Vittoriano V Corpora Francesca F Vogiatzis Danai D Pinto Antonio A
Oncotarget 20170529 37
<h4>Background</h4>Anderson-Fabry disease (AFD) is an inborn lysosomal enzymopathy resulting from the deficient or absent activity of the lysosomal exogalactohydrolase, α-galactosidase A. This deficiency, results in the altered metabolism of glycosphingolipids which leads to their accumulation in lysosomes, thus to cellular and vascular dysfunction. To date, numerous mutations (according to recent data more than 1000 mutations) have been reported in the GLA intronic and exonic mutations. Traditi ...[more]